Vident Advisory LLC Acquires 127,518 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Vident Advisory LLC increased its holdings in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 535.5% in the fourth quarter, HoldingsChannel reports. The firm owned 151,331 shares of the company’s stock after buying an additional 127,518 shares during the period. Vident Advisory LLC’s holdings in Dr. Reddy’s Laboratories were worth $2,390,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 423.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,863 shares of the company’s stock worth $29,000 after acquiring an additional 1,507 shares during the period. Glass Jacobson Investment Advisors llc boosted its holdings in shares of Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. Glass Jacobson Investment Advisors llc now owns 2,000 shares of the company’s stock worth $32,000 after acquiring an additional 1,600 shares during the period. POM Investment Strategies LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 400.0% during the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock worth $36,000 after acquiring an additional 1,820 shares during the period. Farther Finance Advisors LLC boosted its holdings in shares of Dr. Reddy’s Laboratories by 461.0% during the fourth quarter. Farther Finance Advisors LLC now owns 2,547 shares of the company’s stock worth $40,000 after acquiring an additional 2,093 shares during the period. Finally, Sierra Ocean LLC bought a new stake in shares of Dr. Reddy’s Laboratories during the fourth quarter worth approximately $43,000. Institutional investors own 3.85% of the company’s stock.

Dr. Reddy’s Laboratories Stock Down 1.1%

NYSE RDY opened at $14.34 on Thursday. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02. Dr. Reddy’s Laboratories Limited has a 1-year low of $12.26 and a 1-year high of $16.89. The company has a 50 day moving average of $13.54 and a 200-day moving average of $14.03. The company has a market cap of $11.97 billion, a price-to-earnings ratio of 22.83 and a beta of 0.33.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Friday, May 9th. The company reported $0.22 earnings per share for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. The company had revenue of $996.17 million during the quarter, compared to the consensus estimate of $83.70 billion. On average, equities research analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded Dr. Reddy’s Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, May 8th.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.